CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Liu, Yuhong ^a   O’Leary, Claire E ^b   Wang, Liang Chuan S ^c   Bhatti, Tricia R ^a   Dai, Ning ^a   Kapoor, Veena ^c   Liu, Peihui ^d   Mei, Junjie ^a,e   Guo, Lei ^e   Oliver, Paula M ^a,b   Albelda, Steven M ^c   Worthen, G Scott ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e INSTITUTE OF MEDICAL BIOLOGY   (China)

Author keywords

CD11b+Ly6G+Cells; IL 17 and CD8+T cells; Neutrophils; Tumor

Indexed keywords

CD11B ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; T CELL DEPLETION; TUMOR GROWTH; TUMOR VOLUME;

EID: 84954436770     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1061175     Document Type: Article

References (53)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx. doi. org/ 10. 1126/science. 1203486
2. Brandau S, Dumitru CA, Lang S. Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol 2013; 35(2):163-76; PMID:23007469; http://dx. doi. org/10. 1007/s00281-012-0344-6
3. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011; 71:2411-6; PMID:21427354; http://dx. doi. org/ 10. 1158/0008-5472. CAN-10-2583
4. Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, Suttmann H, Schenck M, Welling J, Zabel P et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 2011; 89:311-7; PMID:21106641; http:// dx. doi. org/10. 1189/jlb. 0310162
5. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, Boireau W, Simon B, Ryffel B, Connat JL et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19(1):57-64; PMID:23202296
6. Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis 2012; 33:949-55; PMID:22425643; http://dx. doi. org/10. 1093/carcin/ bgs123
7. Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011; 20:300-14; PMID:21907922; http://dx. doi. org/ 10. 1016/j. ccr. 2011. 08. 012
8. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGFbeta: "N1" versus "N2" TAN. Cancer cell 2009; 16:183-94; PMID:19732719; http://dx. doi. org/ 10. 1016/j. ccr. 2009. 06. 017
9. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res 2012; 18:5212-23; PMID:22837179; http://dx. doi. org/10. 1158/1078-0432. CCR-12-1108
10. Srivastava MK, Zhu L, Harris-White M, Kar U, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012; 7:e40677; PMID:22815789; http://dx. doi. org/ 10. 1371/journal. pone. 0040677
11. Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumorderived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 2011; 6:e27690; PMID:22110722; http://dx. doi. org/10. 1371/journal. pone. 0027690
12. Sawant A, Schafer CC, Jin TH, Zmijewski J, Tse HM, Roth J, Sun Z, Siegal GP, Thannickal VJ, Grant SC et al. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res 2013; 73:6609-20; PMID:24085788; http://dx. doi. org/10. 1158/0008-5472. CAN-13-0987
13. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004; 172:989-99; PMID:14707072; http://dx. doi. org/10. 4049/jimmunol. 172. 2. 989
14. Seung LP, Rowley DA, Dubey P, Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A 1995; 92:6254-8; PMID:7603979; http://dx. doi. org/10. 1073/pnas. 92. 14. 6254
15. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008; 267:226-44; PMID:18579287; http://dx. doi. org/10. 1016/j. canlet. 2008. 04. 050
16. Forlow SB, Schurr JR, Kolls JK, Bagby GJ, Schwarzenberger PO, Ley K. Increased granulopoiesis through interleukin-17 and granulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient mice. Blood 2001; 98:3309-14; PMID:11719368; http://dx. doi. org/10. 1182/blood. V98. 12. 3309
17. Mei J, Liu Y, Dai N, Hoffmann C, Hudock KM, Zhang P, Guttentag SH, Kolls JK, Oliver PM, Bushman FD et al. Cxcr2 and Cxcl5 regulate the IL-17/GCSF axis and neutrophil homeostasis in mice. J Clin Invest 2012; 122:974-86; PMID:22326959; http://dx. doi. org/10. 1172/JCI60588
18. Liu Y, Mei J, Gonzales L, Yang G, Dai N, Wang P, Zhang P, Favara M, Malcolm KC, Guttentag S et al. IL-17A and TNF-alpha exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitro. J Immunol 2011; 186:3197-205; PMID:21282514; http://dx. doi. org/ 10. 4049/jimmunol. 1002016
19. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005; 22:285-94; PMID:15780986; http://dx. doi. org/ 10. 1016/j. immuni. 2005. 01. 011
20. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28:454-67; PMID:18400188; http://dx. doi. org/10. 1016/j. immuni. 2008. 03. 004
21. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194:519-27; PMID:11514607; http://dx. doi. org/ 10. 1084/jem. 194. 4. 519
22. Chen D, Hu Q, Mao C, Jiao Z, Wang S, Yu L, Xu Y, Dai D, Yin L, Xu H. Increased IL-17-producing CD4 (+) T cells in patients with esophageal cancer. Cell Immunol 2012; 272(2):166-74; http://dx. doi. org/ 10. 1016/j. cellimm. 2011. 10. 015
23. Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S, Kamada M, Aono T. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 2001; 282:735-8; PMID:11401524; http://dx. doi. org/10. 1006/bbrc. 2001. 4618
24. Lee JJ, Chang YL, Lai WL, Ko JY, Kuo MY, Chiang CP, Azuma M, Chen CW, Chia JS. Increased prevalence of interleukin-17-producing CD4(+) tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck 2011; 33:1301-8; PMID:21837700; http://dx. doi. org/ 10. 1002/hed. 21607
25. He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD, Xu H. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol 2010; 184:2281-8; PMID:20118280; http:// dx. doi. org/10. 4049/jimmunol. 0902574
26. Reppert S, Boross I, Koslowski M, Tureci O, Koch S, Lehr HA, Finotto S. A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun 2011; 2:600; PMID:22186896; http://dx. doi. org/10. 1038/ncomms1609
27. Reppert S, Koch S, Finotto S. IL-17A is a central regulator of lung tumor growth. Oncoimmunology 2012; 1:783-5; PMID:22934282; http://dx. doi. org/10. 4161/ onci. 19735
28. Challacombe JM, Suhrbier A, Parsons PG, Jones B, Hampson P, Kavanagh D, Rainger GE, Morris M, Lord JM, Le TT et al. Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006; 177:8123-32; PMID:17114487; http://dx. doi. org/10. 4049/ jimmunol. 177. 11. 8123
29. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21-6; PMID:8548765
30. Riese MJ, Wang LC, Moon EK, Joshi RP, Ranganathan A, June CH, Koretzky GA, Albelda SM. Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res 2013; 73:3566-77; PMID:23576561; http://dx. doi. org/ 10. 1158/0008-5472. CAN-12-3874
31. Viola A, Sarukhan A, Bronte V, Molon B. The pros and cons of chemokines in tumor immunology. Trends Immunol 2012; 33:496-504; PMID:22726608; http:// dx. doi. org/10. 1016/j. it. 2012. 05. 007
32. Dubinett SM, Lee JM, Sharma S, Mule JJ. Chemokines: can effector cells be redirected to the site of the tumor? Cancer J 2010; 16:325-35; PMID:20693843; http://dx. doi. org/10. 1097/ PPO. 0b013e3181eb33bc
33. Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005; 65:11752-61; PMID:16357188; http:// dx. doi. org/10. 1158/0008-5472. CAN-05-1658
34. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004; 172:2853-60; PMID:14978086; http://dx. doi. org/10. 4049/jimmunol. 172. 5. 2853
35. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 2005; 16:593-609; PMID:16046180; http://dx. doi. org/10. 1016/j. cytogfr. 2005. 04. 007
36. de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006; 13:118-37; PMID:16627962; http://dx. doi. org/10. 1159/ 000092969
37. Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD et al. Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis. Clin Cancer Res 2013; 19:3404-15; PMID:23653148; http://dx. doi. org/10. 1158/1078-0432. CCR-13-0525
38. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009; 86:1065-73; PMID:19741157; http://dx. doi. org/10. 1189/jlb. 0609385
39. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 2008; 84:623-30; PMID:18467655; http://dx. doi. org/ 10. 1189/jlb. 1107762
40. Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 2007; 25:1562-9; PMID:17443000; http://dx. doi. org/ 10. 1200/JCO. 2006. 09. 0274
41. Nagaraj S, Collazo M, Corzo CA, Youn JI, Ortiz M, Quiceno D, Gabrilovich DI. Regulatory myeloid suppressor cells in health and disease. Cancer Res 2009; 69:7503-6; PMID:19752086; http://dx. doi. org/ 10. 1158/0008-5472. CAN-09-2152
42. Medina-Echeverz J, Fioravanti J, Zabala M, Ardaiz N, Prieto J, Berraondo P. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 2011; 186:807-15; PMID:21148040; http://dx. doi. org/10. 4049/ jimmunol. 1001483
43. Kish DD, Gorbachev AV, Parameswaran N, Gupta N, Fairchild RL. Neutrophil expression of Fas ligand and perforin directs effector CD8 T cell infiltration into antigen-challenged skin. J Immunol 2012; 189:2191-202; PMID:22815291; http://dx. doi. org/10. 4049/ jimmunol. 1102729
44. Jinesh GG, Kamat AM. Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. Oncoimmunology 2012; 1:1161-2; PMID:23170264; http://dx. doi. org/ 10. 4161/onci. 20928
45. Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009; 27:4709-17; PMID:19720929; http://dx. doi. org/ 10. 1200/JCO. 2008. 18. 9498
46. Souto JC, Vila L, Bru A. Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev 2011; 31:311-63; PMID:19967776; http://dx. doi. org/ 10. 1002/med. 20185
47. Piccard H, Muschel RJ, Opdenakker G. On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol 2012; 82:296-309; PMID:21798756; http://dx. doi. org/10. 1016/j. critrevonc. 2011. 06. 004
48. Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S. Neutrophils and granulocytic myeloidderived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 2012; 61:1155-67; PMID:22692756; http://dx. doi. org/10. 1007/ s00262-012-1294-5
49. Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V, Horng W, Fridlender G, Bayuh R, Worthen GS et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS One 2012; 7:e31524; PMID:22348096; http://dx. doi. org/ 10. 1371/journal. pone. 0031524
50. Mishalian I, Bayuh R, Levy L, Zolotarov L, Michaeli J, Fridlender ZG. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother 2013; 62:1745-56; PMID:24092389; http://dx. doi. org/ 10. 1007/s00262-013-1476-9
51. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http:// dx. doi. org/10. 1038/nri2506
52. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001; 97:339-45; PMID:11154206; http://dx. doi. org/ 10. 1182/blood. V97. 2. 339
53. Hayata K, Iwahashi M, Ojima T, Katsuda M, Iida T, Nakamori M, Ueda K, Nakamura M, Miyazawa M, Tsuji T et al. Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice. PLoS One 2013; 8:e53131; PMID:23372655; http://dx. doi. org/ 10. 1371/journal. pone. 0053131